ScholarLens Back to search
1990•Acta Psychiatrica ScandinavicaRequires access

Moclobemide (Ro 11‐1163) versus imipramine in the treatment of depression

MASSIMO CASACCHIA, E. Moll

Open publisher page 9 citations

Abstract

Moclobemide and imipramine were compared single-blind in 2 groups of 20 depressed patients (75% and 65% endogenous depression respectively). There was no significant difference between the 2 groups in improvement on the Hamilton Rating Scale for Depression. The final overall assessment of efficacy was good or very good in 80% of the moclobemide patients and 55% on imipramine. Tolerance was good to very good in 95% of moclobemide patients, compared with 80% on imipramine. No severe adverse effects were reported in either group.

About this research paper

What this paper is about

Moclobemide and imipramine were compared single-blind in 2 groups of 20 depressed patients (75% and 65% endogenous depression respectively). There was no significant difference between the 2 groups in improvement on the Hamilton Rating Scale for Depression. The final overall assessment of efficacy was good or very good in 80% of the moclobemide patients and 55% on imipramine. Tolerance was good to very good in 95% of moclobemide patients, compared with 80% on imipramine. No severe adverse effects were reported in either group.

Why it matters

OpenAlex reports 9 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Moclobemide and imipramine were compared single-blind in 2 groups of 20 depressed patients (75% and 65% endogenous depression respectively). There was no significant difference between the 2 groups in improvement on the Hamilton Rating Scale for Depression. The final overall assessment of efficacy was good or very good in 80% of the moclobemide patients and 55% on imipramine. Tolerance was good to very good in 95% of moclobemide patients, compared with 80% on imipramine. No severe adverse effects were reported in either group.

Key concepts: Moclobemide, Imipramine, Depression (economics), Rating scale, Hamilton Rating Scale for Depression, Psychology, Medicine, Adverse effect

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Moclobemide (Ro 11‐1163) versus imipramine in the treatment of depression — Research Paper | ScholarLens